Cytovia, Cellectis expand partnership to boost collaboration in China

By The Science Advisory Board staff writers

November 22, 2021 -- Cytovia Therapeutics and Cellectis have expanded their partnership on transcription activatorlike effector nuclease (TALEN) gene-edited iNK (NK cells derived from induced pluripotent stem cells, or iPSC) to allow for a broader collaboration in China.

Cellectis will continue its development of a new TALEN, which Cytovia uses to edit iPSCs, according to the two firms. The collaboration now includes a new chimeric antigen receptor target, which will be developed in China by CytoLynx Therapeutics, Cytovia's joint venture.

Cellectis will receive $20 million in Cytovia stock in addition to $805 million in development, regulatory, and sales milestones plus royalties, the two firms said.

Cellectis, Sanofi partner on UCART clinical trials
Sanofi has agreed to supply anti-CD52 monoclonal antibody alemtuzumab for use in a lymphodepleting regimen in Cellectis-sponsored universal chimeric antigen...
Cytovia ramps up production of NK cells ahead of trials
Cytovia Therapeutics has signed two agreements for research and development and manufacturing operations to move the company's chimeric antigen receptor-natural...
Cytovia, Cellectis partner on gene-edited NK cells
Cytovia Therapeutics and Cellectis have entered into a strategic research and development collaboration to develop gene-edited natural killer (NK) and...
Cytovia licenses CAR NK tech to NCI
Cytovia Therapeutics has signed a licensing agreement with the National Cancer Institute (NCI), part of the National Institutes of Health, to apply its...

Copyright © 2021

Microscopy and Microanalysis Meeting
July 31 - August 4
Portland, Oregon United States
Glasgow International Health Festival
August 24-27
Glasgow, Glasgow City United Kingdom
Pharma Competitive Intelligence Conference and Exhibition
September 21-22
Newark, New Jersey United States
BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter